The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 14 of those trials with a site in Non-small Cell Lung Cancer.
14 of the 2,500 most recently authorised trials in this register list a site in Non-small Cell Lung Cancer; 4 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
| Phase | Trials | Share |
|---|---|---|
| Phase II | 7 | 50% |
| Phase III | 4 | 28.6% |
| Phase I/II | 2 | 14.3% |
| Phase I | 1 | 7.1% |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca AB | 2 |
| AbbVie Deutschland GmbH & Co. KG | 1 |
| Academisch Ziekenhuis Maastricht | 1 |
| AIO-Studien gGmbH | 1 |
| BioNTech SE | 1 |
| Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. | 1 |
| Bristol-Myers Squibb Services Unlimited Company | 1 |
| Janssen Cilag International | 1 |
| Maia Biotechnology Inc. | 1 |
| Merus B.V. | 1 |